What is GNTA's current stock price?

GNTA (Genenta Science S.p.A.) is currently trading at $0.58 with a market cap of $11.1M.

What sector is Genenta Science S.p.A. in?

Genenta Science S.p.A. (GNTA) operates in the Healthcare sector, specifically in the Biotechnology industry.

InvestLog

GNTA Genenta Science S.p.A.

Healthcare

$0.58+0.00%OpenMarket Cap: $11.1M

As of 2026-05-26

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

0.48

P/S

0.00

EV/EBITDA

-1.84

DCF Value

$-0.13

FCF Yield

-80.9%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-36.8%

ROA

-19.6%

ROIC

-21.3%

Financials

View All

Period	Revenue	Net Income	EPS
Q4 null	$0.00	$-2.7M	$—
FY null	$0.00	$-6.3M	$—
Q2 null	$0.00	$-3.6M	$—
Q4 null	$0.00	$-5.1M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$—

Target (Median)

$—

Target Range

$— - $—

1 Strong Buy0 Buy0 Hold0 Sell0 Strong Sell

Trading Activity

Insider Trades

View All

Paracchi Pierluigidirector, 10 percent owner, officer: Chief Executive Officer

SellTue May 05

SLANSKY RICHARD Bofficer: Chief Financial Officer

SellWed Apr 01

Sharei Armondirector

SellWed Apr 01

PARACCHI GIACOMOANTONIOdirector

SellWed Apr 01

Mutti Miguel Mariadirector

SellWed Apr 01

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.73

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.

Peers

CVM

SER